Navigation Links
Cobalis Corp. Receives $415,000 First Purchase Order from Major Retail Pharmacy for PreHistin® Allergy Defense Formula
Date:1/12/2011

IRVINE, Calif., Jan. 12, 2011 /PRNewswire/ -- Cobalis Corp., (Pink Sheets: CLSC) makers of PreHistin® Allergy Defense Formula, announced today that they have received a $415,000 opening purchase order via the Direct EDI ordering and invoicing system from one of the nation's two leading chain pharmacies, as well as opening orders from several other national and regional healthcare product distributors and retailers; thus signaling the launch of PreHistin®'s national retail marketing campaign.  The aggregate purchase orders call for delivery of over 25,000 boxes of PreHistin® to some 5,000 pharmacies nationwide in the country's top allergy cities.  Delivery of PreHistin® will commence in mid-February to enable PreHistin® to appear on pharmacy shelves in time for the spring allergy season.

Cobalis plans to support its retail sales program by launching 30-second and 60-second branded television commercials in top market cities announcing that PreHistin® is now available at these pharmacies.   These commercials will feature Dr. Paul Ratner, MD - one of the country's leading allergists and clinical researchers - as saying: "PreHistin® can help allergy sufferers reset their body's normal response to seasonal and year-round allergens – which is no allergic response at all," distinguishing PreHistin® from current after-the-fact antihistamines.  PreHistin® does not require a prescription, is 100% non-drowsy and has no known side effects.

Martin Marion, Cobalis' CEO said, "We are extremely proud that one of the nation's most prestigious and respected healthcare retailers has selected PreHistin® Allergy Defense Formula to be part of its line of consumer healthcare pharmacy products.  We will put a major effort behind supporting these retailers, driving consumers to the pharmacies, and to bring the PreHistin® message aggressively to the more than 60 million Americans who suffer needlessly from seasonal and year-round allergies.  This is the game-changer Cobalis has been preparing for, transitioning Cobalis from a research and development company to a fundamental revenue-generating operation."

Cobalis expects to quickly expand its retail presence for PreHistin® Allergy Defense Formula to other significant retailers coast-to-coast and to build a significant brand presence for PreHistin®.  In addition, Cobalis plans to unveil its new online marketing website network within the next few weeks, which will be supported by an aggressive SEO and SEM campaign.

ABOUT PREHISTIN® ALLERGY DEFENSE FORMULAPreHistin® Allergy Defense Formula is a unique, patented cobalamin complex product that helps rebalance the immune system to lower allergen antibody IgE levels, and regulate the release of symptom-linked histamine which is linked to the onset of symptoms such as sneezing, itchy watery eyes, runny nose and nasal congestion.  PreHistin® is a cherry-flavored lozenge that is dissolved under the tongue and then swallowed twice a day for 21 to 30 days, usually before the pollen season.  PreHistin® has no known side effects, is 100% non-drowsy, and has no contraindications with any other medications.  In clinical trials on thousands of allergy sufferers, PreHistin® was shown to be safe and effective in reducing nasal symptoms.

ABOUT COBALIS CORP.—PREHISTIN®Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company.  Its flagship product, PreHistin® Allergy Defense Formula, "The World's FIRST Pre-Histamine", is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens.  PreHistin® is now available without prescription for both long-term and daily use.

For PreHistin® product information please visit www.PreHistin.com or call toll free 1-877-4POLLEN (1-877-476-5536).  For additional company information please visit the corporate website at www.Cobalis.comCONTACTCobalis Corp.16795 Von Karman, Suite 200Irvine, CA 92606949-260-0123 (pacific time)Chas Radovich, PresidentMartin Marion, CEOinfo(at)cobalis(dot)com
'/>"/>

SOURCE Cobalis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cobalis Corp. Provides Marketing Update Conference Call for Investors
2. Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
5. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
8. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
9. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
10. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
11. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
Breaking Medicine News(10 mins):